GENE ONLINE|News &
Opinion
Blog

Breast Cancer
Seattle Genetics Enters Breast Cancer Market with Tukysa
2020-04-21
Yet Another Feather in Merck’s Crown, Keytruda Meets Endpoint in Phase 3 Trial for Triple Negative Breast Cancer
2020-02-13
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
Tecentriq/Arbaxane Combo Becomes the First FDA Approved Immunotherapy Regimen for Breast Cancer Treatment
2019-03-14
Herceptin Hylecta bags FDA approval for HER2-Positive Breast Cancer Treatment
2019-03-04
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
Expedited Approval of Vitrakvi® Marks Many Firsts in Cancer Therapy
2018-12-04
Pfizer’s Talzenna approved for breast cancer treatment
2018-10-25
Roche’s breast cancer drug, Kadcyla succeeds phase III trial
2018-10-22
CFDA processes priority review of BGI’s BRCA1/2 gene testing kit
2018-07-11
PARP inhibitors in cancer – BRCA or no BRCA
2018-07-03
1 2 3 4
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top